{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:00:48Z","timestamp":1789894848332,"version":"4.0.1"},"reference-count":47,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.3724\/abbs.2026117","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:27:36Z","timestamp":1782887256000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis"],"prefix":"10.3724","author":[{"given":"Yinghan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fude","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"CITATION1","unstructured":"Rahimi N, Gupta S. Biochemistry, Ketogenesis.  In: StatPearls [Internet] . Treasure Island (FL): StatPearls Publishing 2026 Jan ."},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","volume":"25","author":"Puchalska P","year":"2017","unstructured":"Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab, 2017, 25: 262-284.","journal-title":"Cell Metab"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.plipres.2013.12.001","volume":"53","author":"Nakamura MT","year":"2014","unstructured":"Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res, 2014, 53: 124-144.","journal-title":"Prog Lipid Res"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejim.2023.07.005","volume":"117","author":"Barski L","year":"2023","unstructured":"Barski L, Golbets E, Jotkowitz A, Schwarzfuchs D. Management of diabetic ketoacidosis. Eur J Internal Med, 2023, 117: 38-44.","journal-title":"Eur J Internal Med"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1573399812666160421121307","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review.  Curr Diabetes Rev, 2017, 13: 315-321.","journal-title":"Curr Diabetes Rev"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"e12623","DOI":"10.1111\/jpi.12623","volume":"68","author":"Park JH","year":"2020","unstructured":"Park JH, Seo I, Shim HM, Cho H. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice. J Pineal Res, 2020, 68:","journal-title":"J Pineal Res"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"e13665","DOI":"10.7759\/cureus.13665","volume":"13","author":"Somagutta MR","year":"2021","unstructured":"Somagutta MR, Agadi K, Hange N, Jain MS, Batti E, Emuze BO, Amos-Arowoshegbe EO. Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: a focused review of pathophysiology, risk factors, and triggers. Cureus, 2021, 13:","journal-title":"Cureus"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"105572","DOI":"10.1016\/j.phrs.2021.105572","volume":"167","author":"Xu S","year":"2021","unstructured":"Xu S, Feng Y, He W, Xu W, Xu W, Yang H, Li X. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res, 2021, 167:","journal-title":"Pharmacol Res"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"114882","DOI":"10.1016\/j.biopha.2023.114882","volume":"163","author":"Wang C","year":"2023","unstructured":"Wang C, Dai S, Zhao X, Zhang Y, Gong L, Fu K, Ma C. Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies. Biomed Pharmacother, 2023, 163:","journal-title":"Biomed Pharmacother"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","volume":"161","author":"Liu J","year":"2015","unstructured":"Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell, 2015, 161: 999-1011.","journal-title":"Cell"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmet.2015.08.005","volume":"22","author":"Ma X","year":"2015","unstructured":"Ma X, Xu L, Alberobello AT, Gavrilova O, Bagattin A, Skarulis M, Liu J. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1\u03b1 transcriptional axis. Cell Metab, 2015, 22: 695-708.","journal-title":"Cell Metab"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molmet.2016.11.002","volume":"6","author":"Zhang Y","year":"2017","unstructured":"Zhang Y, Geng C, Liu X, Li M, Gao M, Liu X, Fang F. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1. Mol Metab, 2017, 6: 138-147.","journal-title":"Mol Metab"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"e62068","DOI":"10.1371\/journal.pone.0062068","volume":"8","author":"Kim JE","year":"2013","unstructured":"Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE, Kim HW. Celastrol, an NF-\u03baB inhibitor, improves insulin resistance and attenuates renal injury in db\/db mice. PLoS One, 2013, 8:","journal-title":"PLoS One"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jcjd.2018.07.002","volume":"43","author":"Zhang X","year":"2019","unstructured":"Zhang X, Xue XC, Wang Y, Cao FF, You J, Uzan G, Peng B. Celastrol reverses palmitic acid-induced insulin resistance in HepG2 Cells via restoring the miR-223 and GLUT4 pathway. Can J Diabetes, 2019, 43: 165-172.","journal-title":"Can J Diabetes"},{"key":"CITATION15","doi-asserted-by":"crossref","unstructured":"Li WC, Ralphs KL, Tosh D. Isolation and culture of adult mouse hepatocytes.  Methods Mol Biol  2010, 633: 185\u2013196 .","DOI":"10.1007\/978-1-59745-019-5_13"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"108722","DOI":"10.1016\/j.bioorg.2025.108722","volume":"163","author":"Wang L","year":"2025","unstructured":"Wang L, Lin F, Liu J, Jia Z, Zhu M, Liu Y, Li Y. Revealing a new target: celastrol alleviates pulmonary fibrosis by inhibiting PCAF. Bioorg Chem, 2025, 163:","journal-title":"Bioorg Chem"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/ijms17122093","volume":"17","author":"Grabacka M","year":"2016","unstructured":"Grabacka M, Pierzchalska M, Dean M, Reiss K. Regulation of ketone body metabolism and the role of PPAR\u03b1. Int J Mol Sci, 2016, 17:","journal-title":"Int J Mol Sci"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","volume":"3","author":"Kersten S","year":"2014","unstructured":"Kersten S. Integrated physiology and systems biology of PPAR\u03b1. Mol Metab, 2014, 3: 354-371.","journal-title":"Mol Metab"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/metabo14010064","volume":"14","author":"Luo M","year":"2024","unstructured":"Luo M, Wang Y, Ma Y, Li J, Wang J, Liu C. Celastrol stabilizes glycolipid metabolism in hepatic steatosis by binding and regulating the peroxisome proliferator-activated receptor \u03b3 signaling pathway. Metabolites, 2024, 14:","journal-title":"Metabolites"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Liu Y","year":"2022","unstructured":"Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res, 2022, 50: W159-W164.","journal-title":"Nucleic Acids Res"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","volume":"26","author":"Cahill GF","year":"2006","unstructured":"Cahill GF. Fuel metabolism in starvation. Annu Rev Nutr, 2006, 26: 1-22.","journal-title":"Annu Rev Nutr"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care, 2015, 38: 1638-1642.","journal-title":"Diabetes Care"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"Fralick M","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med, 2017, 376: 2300-2302.","journal-title":"N Engl J Med"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1093\/emboj\/17.23.6972","volume":"17","author":"Meertens LM","year":"1998","unstructured":"Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPAR\u03b1. EMBO J, 1998, 17: 6972-6978.","journal-title":"EMBO J"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"157694","DOI":"10.1016\/j.phymed.2025.157694","volume":"150","author":"Zhang H","year":"2025","unstructured":"Zhang H, Lin A, Zhai C, Lai T, Gong X, Wang M, Wu H. Ginsenoside Rd promotes cardiac regeneration through PPARG\/HMGCS2-driven ketone body metabolic reprogramming in myocardial ischemia-reperfusion injury. Phytomedicine, 2025, 150:","journal-title":"Phytomedicine"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"Gross B","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol, 2017, 13: 36-49.","journal-title":"Nat Rev Endocrinol"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1210\/edrv.20.5.0380","volume":"20","author":"Desvergne B","year":"1999","unstructured":"Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev, 1999, 20: 649-688.","journal-title":"Endocrine Rev"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.tem.2023.10.002","volume":"35","author":"Ruppert PMM","year":"2024","unstructured":"Ruppert PMM, Kersten S. Mechanisms of hepatic fatty acid oxidation and ketogenesis during fasting. Trends Endocrinol Metab, 2024, 35: 107-124.","journal-title":"Trends Endocrinol Metab"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11883-005-0053-x","volume":"7","author":"Chinetti-Gbaguidi G","year":"2005","unstructured":"Chinetti-Gbaguidi G, Fruchart JC, Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep, 2005, 7: 396-401.","journal-title":"Curr Atheroscler Rep"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1111\/acel.12874","volume":"18","author":"Chellappa K","year":"2019","unstructured":"Chellappa K, Perron IJ, Naidoo N, Baur JA. The leptin sensitizer celastrol reduces age-associated obesity and modulates behavioral rhythms. Aging Cell, 2019, 18:","journal-title":"Aging Cell"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.metabol.2016.01.009","volume":"65","author":"Choi SK","year":"2016","unstructured":"Choi SK, Park S, Jang S, Cho HH, Lee S, You S, Kim SH. Cascade regulation of PPAR\u03b32 and C\/EBP\u03b1 signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes. Metabolism, 2016, 65: 646-654.","journal-title":"Metabolism"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"114705","DOI":"10.1016\/j.biopha.2023.114705","volume":"162","author":"Song J","year":"2023","unstructured":"Song J, He GN, Dai L. A comprehensive review on celastrol, triptolide and triptonide: insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Biomed Pharmacother, 2023, 162:","journal-title":"Biomed Pharmacother"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"1137289","DOI":"10.3389\/fphar.2024.1137289","volume":"15","author":"Sun Y","year":"2024","unstructured":"Sun Y, Wang C, Li X, Lu J, Wang M. Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity. Front Pharmacol, 2024, 15:","journal-title":"Front Pharmacol"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.3390\/molecules26144124","volume":"26","author":"Liu M","year":"2021","unstructured":"Liu M, Chen M, Luo Y, Wang H, Huang H, Peng Z, Li M. Lipidomic profiling of ipsilateral brain and plasma after celastrol post-treatment in transient middle cerebral artery occlusion mice model. Molecules, 2021, 26:","journal-title":"Molecules"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ajh.2010.75","volume":"23","author":"Yu X","year":"2010","unstructured":"Yu X, Tao W, Jiang F, Li C, Lin J, Liu C. Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens, 2010, 23: 895-903.","journal-title":"Am J Hypertens"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12906-020-03050-y","volume":"20","author":"Nie Y","year":"2020","unstructured":"Nie Y, Fu C, Zhang H, Zhang M, Xie H, Tong X, Li Y. Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K\/AKT pathway. BMC Complement Med Ther, 2020, 20:","journal-title":"BMC Complement Med Ther"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physiolgenomics.00072.2024","volume":"57","author":"Faheem H","year":"2025","unstructured":"Faheem H, Alawadhi R, Basha EH, Ismail R, Ibrahim HA, Elshamy AM, Motawea SM. Ameliorating immune-dependent inflammation and apoptosis by targeting TLR4\/MYD88\/NF-\u03baB pathway by celastrol mitigates the diabetic reproductive dysfunction. Physiol Genomics, 2025, 57: 103-114.","journal-title":"Physiol Genomics"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"Loomba R","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184: 2537-2564.","journal-title":"Cell"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"946474","DOI":"10.3389\/fphys.2022.946474","volume":"13","author":"Mooli RGR","year":"2022","unstructured":"Mooli RGR, Ramakrishnan SK. Emerging role of hepatic ketogenesis in fatty liver disease. Front Physiol, 2022, 13:","journal-title":"Front Physiol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"Dhillon S","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs, 2019, 79: 1135-1146.","journal-title":"Drugs"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1007\/s11427-024-2602-7","volume":"67","author":"Zhang W","year":"2024","unstructured":"Zhang W, Wang L, Wang Y, Fang Y, Cao R, Fang Z, Han D. Inhibition of the RXRA-PPAR\u03b1-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model. Sci China Life Sci, 2024, 67: 2678-2691.","journal-title":"Sci China Life Sci"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/03008207.2025.2561655","volume":"67","author":"Pyo MK","year":"2026","unstructured":"Pyo MK, Ko JH, Lim DS, Gwon HJ, Abd El-Aty AM, Ahmet Aydemir H\u0131, Jeong JH. Dapagliflozin attenuates lipotoxic tenocyte injury via PPAR\u03b1 activation and irisin-driven antioxidant pathways. Connective Tissue Res, 2026, 67: 38-50.","journal-title":"Connective Tissue Res"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"e22451","DOI":"10.1002\/jbt.22451","volume":"34","author":"Gamil NM","year":"2020","unstructured":"Gamil NM, Abd El Fattah MA, Ahmed MAE, Maklad YA, Gamal El Din AA, Eid NI. Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats. J Biochem Mol Tox, 2020, 34:","journal-title":"J Biochem Mol Tox"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"967822","DOI":"10.3389\/fendo.2022.967822","volume":"13","author":"Bai Z","year":"2022","unstructured":"Bai Z, Xie T, Liu T, Chen Z, Yu L, Zhang C, Luo J. An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. Front Endocrinol, 2022, 13:","journal-title":"Front Endocrinol"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"175172","DOI":"10.1016\/j.ejphar.2022.175172","volume":"931","author":"Khalaf EM","year":"2022","unstructured":"Khalaf EM, Hassan HM, El-Baz AM, Shata A, Khodir AE, Yousef ME, Elgharabawy RM.  A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: role of oxidative stress, gut microbiota, and PPAR\u03b3 activation . Eur J Pharmacol, 2022, 931:","journal-title":"Eur J Pharmacol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"114863","DOI":"10.1016\/j.fct.2024.114863","volume":"191","author":"El-Sawy WSM","year":"2024","unstructured":"El-Sawy WSM, El-Bahrawy AH, Messiha BAS, Hemeida RAM, Khalaf MM. The impact of PPAR-\u03b3\/Nrf-2\/HO-1, NF-\u03baB\/IL-6\/ Keap-1, and Bcl-2\/caspase-3\/ATG-5 pathways in mitigation of DOX-induced cardiotoxicity in an animal model: the potential cardioprotective role of oxyresveratrol and\/or dapagliflozin. Food Chem Toxicol, 2024, 191:","journal-title":"Food Chem Toxicol"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1007\/s00210-024-03608-4","volume":"398","author":"El-Sawy WSM","year":"2025","unstructured":"El-Sawy WSM, Khalaf MM, El-Bahrawy AH, Messiha BAS, Hemeida RAM. Oxyresveratrol and\/or dapagliflozin attenuate doxorubicin-induced nephrotoxicity via modulation of PPAR-\u03b3\/Nrf-2\/HO-1, NF-\u03baB\/TNF-\u03b1\/Keap-1, and Bcl-2\/Caspase-3\/ATG-5 signaling pathways in rats. Naunyn Schmiedebergs Arch Pharmacol, 2025, 398: 5955-5967.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/F9746AFCAAE94618B8DEB8F9F2EC2FEC","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026117","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/F9746AFCAAE94618B8DEB8F9F2EC2FEC","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:22:54Z","timestamp":1789892574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026117","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}